{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:48:54Z","timestamp":1784828934918,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.virol.2023.109885","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:21:41Z","timestamp":1694755301000},"page":"109885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma"],"prefix":"10.1016","volume":"587","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guishan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2023.109885_bib1","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1038\/s41388-019-0737-2","article-title":"Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model","volume":"38","author":"Alessandrini","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.virol.2023.109885_bib2","article-title":"Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy","volume":"2","author":"Belcaid","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.virol.2023.109885_bib3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/eji.200838921","article-title":"Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg","volume":"39","author":"Biollaz","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.virol.2023.109885_bib4","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1158\/1078-0432.CCR-12-3314","article-title":"Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages","volume":"19","author":"Bloch","year":"2013","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.virol.2023.109885_bib5","doi-asserted-by":"crossref","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2023.109885_bib6","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3892\/mmr.2014.2987","article-title":"Novel oncolytic adenovirus sensitizes renal cell carcinoma cells to radiotherapy via mitochondrial apoptotic cell death","volume":"11","author":"Chen","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.virol.2023.109885_bib7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib8","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","article-title":"Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action","volume":"180","author":"Dubois","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2023.109885_bib9","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/eji.200636329","article-title":"IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL","volume":"37","author":"Dubsky","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.virol.2023.109885_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2023.109885_bib11","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2023.109885_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.virol.2023.109885_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108193","article-title":"Clinical advances in oncolytic virotherapy for pediatric brain tumors","volume":"239","author":"Ghajar-Rahimi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.virol.2023.109885_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/neuonc\/noq001","article-title":"Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo\/neg monocytes, tumor factors, and dexamethasone","volume":"12","author":"Gustafson","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib15","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib16","first-page":"493","article-title":"Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment","volume":"19","author":"Hardcastle","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib17","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2023.109885_bib18","first-page":"2584","article-title":"Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma","volume":"124","author":"Jin","year":"2011","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.virol.2023.109885_bib19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/cgt.2008.46","article-title":"An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors","volume":"16","author":"Lei","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.virol.2023.109885_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib22","doi-asserted-by":"crossref","first-page":"11803","DOI":"10.2147\/CMAR.S274605","article-title":"Antitumor efficacy of oncolytic herpes virus type 1 armed with GM-CSF in murine uveal melanoma xenografts","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.virol.2023.109885_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020186","article-title":"Virus-based immunotherapy of glioblastoma","volume":"11","author":"Martikainen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.virol.2023.109885_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2019.10.012","article-title":"The influence of patient sex on clinical approaches to malignant glioma","volume":"468","author":"Matteoni","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.virol.2023.109885_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib26","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1158\/0008-5472.CAN-06-3244","article-title":"Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4","volume":"67","author":"Post","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2023.109885_bib27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneurol.2015.139","article-title":"Prospects of immune checkpoint modulators in the treatment of glioblastoma","volume":"11","author":"Preusser","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.virol.2023.109885_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib29","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.4049\/jimmunol.169.9.4928","article-title":"Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells","volume":"169","author":"Rubinstein","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2023.109885_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.virol.2023.109885_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/imt-2018-0009","article-title":"Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma","volume":"10","author":"Saha","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.virol.2023.109885_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2023.109885_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fonc.2018.00061","article-title":"DNX-2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas: a case report","volume":"8","author":"Tejada","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.virol.2023.109885_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.virol.2023.109885_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.virol.2023.109885_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2023.109885_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114035","article-title":"Mesenchymal stem cells loaded with Ad5-Ki67\/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma","volume":"157","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.virol.2023.109885_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.virol.2023.109885_bib39","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2023.109885_bib40","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2023.109885_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41419-020-2696-5","article-title":"Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.virol.2023.109885_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00485-1","article-title":"Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci."},{"issue":"11-12","key":"10.1016\/j.virol.2023.109885_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/hum.2019.352","article-title":"Efficacy of an oncolytic adenovirus driven by a chimeric promoter and armed with Decorin against renal cell carcinoma","volume":"31","author":"Zhang","year":"2020","journal-title":"Hum. Gene Ther."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682223002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682223002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:07:51Z","timestamp":1727755671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682223002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":43,"alternative-id":["S0042682223002040"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2023.109885","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2023.109885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109885"}}